Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Operating Expenses: 2013-2024

Historic Operating Expenses for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to $358.9 million.

  • ImmunityBio's Operating Expenses rose 1.54% to $87.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $343.3 million, marking a year-over-year decrease of 6.59%. This contributed to the annual value of $358.9 million for FY2024, which is 1.09% down from last year.
  • Per ImmunityBio's latest filing, its Operating Expenses stood at $358.9 million for FY2024, which was down 1.09% from $362.9 million recorded in FY2023.
  • In the past 5 years, ImmunityBio's Operating Expenses registered a high of $362.9 million during FY2023, and its lowest value of $221.5 million during FY2020.
  • Moreover, its 3-year median value for Operating Expenses was $358.9 million (2024), whereas its average is $357.8 million.
  • In the last 5 years, ImmunityBio's Operating Expenses spiked by 49.54% in 2021 and then dropped by 1.09% in 2024.
  • Over the past 5 years, ImmunityBio's Operating Expenses (Yearly) stood at $221.5 million in 2020, then surged by 49.54% to $331.2 million in 2021, then rose by 6.14% to $351.5 million in 2022, then increased by 3.22% to $362.9 million in 2023, then fell by 1.09% to $358.9 million in 2024.